聚桂醇泡沫硬化剂治疗体表静脉畸形的疗效  

Effect of foam sclerotherapy of lauromacrogol on peripheral venous malformations

作　　者：林玲玲[1] 吕仁荣[1] 徐广琪[1] 牛静静[1] 李龙[1] 霍然[1] 

机构地区：[1]山东大学附属省立医院烧伤整形外科,济南250021

出　　处：《中华医学美学美容杂志》2013年第5期362-364,共3页Chinese Journal of Medical Aesthetics and Cosmetology

摘　　要：目的 探讨注射聚桂醇泡沫硬化剂治疗体表静脉畸形的疗效和安全性.方法 用1％聚桂醇注射液,按Tessari法制作泡沫硬化剂（液∶气为1∶4）.在瘤体内注射泡沫硬化剂治疗体表静脉畸形患者21例.根据瘤体大小、患者年龄决定用药量,每次聚桂醇液体硬化剂用量在1～2 ml,每次聚桂醇泡沫硬化剂用量在8 ml以内,每隔4周重复注射1次,3～5次为1个疗程.根据治疗前后病灶大小、症状改善情况进行疗效评价,将治疗效果分为优、良、中、差4个等级；并通过治疗疗程及期间出现的并发症情况进行安全性评估.结果 21例患者,经3～18个月随访,优10例（47.6％）,良9例（42.9％）,中2例（9.5％）.所有患者每次治疗后均可发生注射部位肿胀,发热5例,21例均未发生严重并发症.结论 聚桂醇泡沫硬化疗法治疗体表静脉畸形安全、有效.Objective To investigate the efficacy and safety of lauromacrogol foam sclerosant in the treatment of peripheral venous malformations.Methods 21 patients with peripheral venous malformations were treated with foam sclerotherapy.The sclerosing foam was produced by Tessari＇s method using 1% lauromacrogol.When necessary,the injections were repeated at an interval of four weeks,and this process contained 3 to 5 injections.Therapeutic outcomes and safety were established by evaluating size of lesion,symptom,duration of treatment and side-effects of treatment before and after treatment.Results 21 patients were followed up for 3 to 18 months.10 cases showed markedly shrinked or even disappeared of treated malformations,9 cases showed a reduction in size over 50 %,and 2 cases showed a reduction in size less 50 %.Local swelling occurred in almost per session,pyrexia in 5 patients,which resolved spontaneously within several days to 1 week.No major complication occurred.Conclusions Foam sclerotherapy using lauromacrogol seems to be a safe and effective therapeutic method for peripheral venous malformations.

关 键 词：聚桂醇 泡沫 硬化疗法 静脉畸形 

分 类 号：R654.3[医药卫生—外科学]